COMPOUND MUSCLE ACTION POTENTIAL AND MOTOR FUNCTION IN CHILDREN WITH SPINAL MUSCULAR ATROPHY

被引：81

作者：

Lewelt, Aga ^{[1
]}

Krosschell, Kristin J. ^{[2
]}

Scott, Charles ^{[3
]}

Sakonju, Ai ^{[4
]}

Kissel, John T. ^{[5
]}

Crawford, Thomas O. ^{[6
]}

Acsadi, Gyula ^{[7
]}

D'anjou, Guy ^{[8
]}

Elsheikh, Bakri ^{[5
]}

Reyna, Sandra P. ^{[4
]}

Schroth, Mary K. ^{[9
]}

Maczulski, Jo Anne ^{[10
]}

Stoddard, Gregory J. ^{[11
]}

Elovic, Elie ^{[1
]}

Swoboda, Kathryn J. ^{[4
]}

机构：

[1] Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT 84132 USA

[2] Northwestern Univ, Feinberg Sch Med, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA

[3] CBS Squared Inc, Ft Washington, PA USA

[4] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT 84132 USA

[5] Ohio State Univ, Med Ctr, Dept Neurol, Columbus, OH 43210 USA

[6] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

[7] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA

[8] Hop St Justine, Div Pediat Neurol, Montreal, PQ H3T 1C5, Canada

[9] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA

[10] Pediat Occupat Therapy Serv, Chicago, IL USA

[11] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA

来源：

MUSCLE & NERVE | 2010年 / 42卷 / 05期

基金：

美国国家卫生研究院;

关键词：

compound muscle action potential; motor function; outcome measures; pediatrics; spinal muscular atrophy; NATURAL-HISTORY; SMA;

D O I：

10.1002/mus.21838

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Reliable outcome measures that reflect the underlying disease process and correlate with motor function in children with SMA are needed for clinical trials. Maximum ulnar compound muscle action potential (CMAP) data were collected at two visits over a 4-6-week period in children with SMA types II and III, 2-17 years of age, at four academic centers. Primary functional outcome measures included the Modified Hammersmith Functional Motor Scale (MHFMS) and MHFMS-Extend. CMAP negative peak amplitude and area showed excellent discrimination between the ambulatory and non-ambulatory SMA cohorts (ROC = 0.88). CMAP had excellent test-retest reliability (ICC = 0.96-0.97, n = 64) and moderate to strong correlation with the MHFMS and MHFMS-Extend (r = 0.61-0.73, n = 68, P < 0.001). Maximum ulnar CMAP amplitude and area is a feasible, valid, and reliable outcome measure for use in pediatric multicenter clinical trials in SMA. CMAP correlates well with motor function and has potential value as a relevant surrogate for disease status. Muscle Nerve 42: 703-708, 2010

引用

页码：703 / 708

页数：6

共 50 条

[1] Impact of disuse muscular atrophy on the compound muscle action potential
Mobach, Theo
Brooks, John
Breiner, Ari
Warman-Chardon, Jodi
Papp, Steven
Gammon, Braden
Nandedkar, Sanjeev D.
Bourque, Pierre R.
[J]. MUSCLE & NERVE, 2020, 61 (01) : 58 - 62
[2] USE OF COMPOUND MOTOR ACTION POTENTIALS TO ASSESS RESPONSE TO INTRATHECAL NUSINERSEN IN CHILDREN WITH SPINAL MUSCULAR ATROPHY
El Kosseifi, Charbel
de la Banda, Martha Gomez Garcia
Barnerias, Christine
Benezit, Audrey
Dabaj, Ivana
Essid, Aben
Haegy-Doehring, Isabelle
Ioos, Christine
Huguet, Martine
Bocassin, Cecilia
Mbieleu, Blaise
Bergounioux, Jean
Desguerre, Isabelle
Quijano-Roy, Susana
Gitiaux, Cyril
[J]. MUSCLE & NERVE, 2019, 60 : S31 - S31
[3] Motor function-muscle strength relationship in spinal muscular atrophy
Merlini, L
Bertini, E
Minetti, C
Mongini, T
Morandi, L
Angelini, C
Vita, G
[J]. MUSCLE & NERVE, 2004, 29 (04) : 548 - 552
[4] Muscle strength and motor function in adolescents and adults with spinal muscular atrophy
Wijngaarde, Camiel A.
Stam, Marloes
Otto, Louise A. M.
Bartels, Bart
Asselman, Fay-Lynn
van Eijk, Ruben P. A.
van den Berg, Leonard H.
Goedee, H. Stephan
Wadman, Renske, I
van der Pol, W. Ludo
[J]. NEUROLOGY, 2020, 95 (14) : E1988 - E1998
[5] Maximum Ulnar Compound Motor Action Potential (CMAP) Is Related to Motor Function in Children with Spinal Muscular Atrophy: Report from the SMA CARNI-VAL Clinical Trial
Lewelt, Aga J.
Krosschell, Kristin J.
Scott, Charles
Kissel, John T.
Crawford, Thomas O.
Acsadi, Gyula
D'Anjou, Guy
Elsheik, Bakri
Reyna, Sandra P.
Lasalle, Bernie A.
Schroth, Mary K.
Simard, Louise R.
Maczulski, Jo Anne
Swoboda, Kathryn J.
[J]. NEUROLOGY, 2010, 74 (09) : A397 - A398
[6] Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy
Boido, Marina
De Amicis, Elena
Valsecchi, Valeria
Trevisan, Marco
Ala, Ugo
Ruegg, Markus A.
Hettwer, Stefan
Vercelli, Alessandro
[J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
[7] Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function
Ueda, Yuki
Egawa, Kiyoshi
Kawamura, Kentaro
Ochi, Noriki
Goto, Takeru
Kimura, Shuhei
Narugami, Masashi
Nakakubo, Sachiko
Nakajima, Midori
Manabe, Atsushi
Shiraishi, Hideaki
[J]. BRAIN & DEVELOPMENT, 2024, 46 (03): : 149 - 153
[8] EUROSMART: motor function and muscle strength in 110 patients with spinal muscular atrophy
Merlini, L
Dahna-Schwake, C
Febrer, A
Hausmanova-Petruse, I
Jedrzejonska, M
Shapira, Y
Taustein, I
Luppi, M
Tizzano, E
Topaloglu, H
Voit, T
Talim, B
[J]. NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 724 - 724
[9] Effects of nusinersen on motor function in children with spinal muscular atrophy: a retrospective study
Chen, Yuyi
Yang, Dongling
Huang, Xuelin
Feng, Juntan
Zhao, Qingqing
Huang, Huixian
Liang, Lushi
Zhang, Xinxin
Ruan, Yiyan
[J]. FRONTIERS IN NEUROLOGY, 2024, 15
[10] Cognitive function in children with spinal muscular atrophy
Sieratzki, JS
Woll, B
[J]. NEUROMUSCULAR DISORDERS, 2002, 12 (7-8) : 693 - 694

← 1 2 3 4 5 →